Melanoma & Skin Cancer

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Michael A. Postow, MD, discusses the potential role for triplet regimens in melanoma management.

NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.

A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.

Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.

Alexander C. Van Akkooi, MD, PhD, FRACS, discusses the prognostic value of minimal sentinel node tumor burden in melanoma.

Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.

Richard Vile, PhD, explains how CAR-T cell therapy works, including the benefits, risks and realities of treatment.

Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.